{"id":"NCT02320669","sponsor":"Seattle Children's Hospital","briefTitle":"Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass","officialTitle":"Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2019-10","completion":"2019-10","firstPosted":"2014-12-19","resultsPosted":"2024-04-09","lastUpdate":"2024-04-09"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Heart Defects"],"interventions":[{"type":"DRUG","name":"Triostat","otherNames":["triiodothyronine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Triostat","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery. Funding Source - FDA OOPD.","primaryOutcome":{"measure":"Time To Extubation","timeFrame":"30 days","effectByArm":[{"arm":"Triostat","deltaMin":46.9,"sd":null},{"arm":"Placebo","deltaMin":48,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.05"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["35093535"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":110},"commonTop":["Cardiac Arrhythmia"]}}